Eton Pharmaceuticals (NASDAQ:ETON) Coverage Initiated at B. Riley

Analysts at B. Riley initiated coverage on shares of Eton Pharmaceuticals (NASDAQ:ETON) in a research note issued to investors on Friday, MarketBeat.com reports. The brokerage set a “buy” rating and a $21.00 price target on the stock. B. Riley’s price objective indicates a potential upside of 56.25% from the stock’s current price. B. Riley also issued estimates for Eton Pharmaceuticals’ Q1 2025 earnings at $0.03 EPS and Q4 2025 earnings at $0.12 EPS.

Other research analysts also recently issued research reports about the stock. HC Wainwright upped their target price on shares of Eton Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, January 6th. Craig Hallum boosted their price target on Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday.

Eton Pharmaceuticals Trading Up 11.9 %

Eton Pharmaceuticals stock opened at $13.44 on Friday. Eton Pharmaceuticals has a 12 month low of $3.03 and a 12 month high of $15.00. The company has a market capitalization of $350.13 million, a price-to-earnings ratio of -61.09 and a beta of 1.38. The business’s fifty day simple moving average is $11.74 and its two-hundred day simple moving average is $7.45.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Eton Pharmaceuticals in the 3rd quarter worth $54,000. Jane Street Group LLC purchased a new stake in Eton Pharmaceuticals in the 3rd quarter worth approximately $90,000. Connor Clark & Lunn Investment Management Ltd. raised its stake in Eton Pharmaceuticals by 86.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock worth $390,000 after acquiring an additional 30,167 shares during the period. Renaissance Technologies LLC lifted its holdings in Eton Pharmaceuticals by 63.8% during the second quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock valued at $350,000 after purchasing an additional 41,469 shares in the last quarter. Finally, Stonepine Capital Management LLC bought a new position in shares of Eton Pharmaceuticals in the second quarter worth approximately $362,000. 27.86% of the stock is currently owned by institutional investors.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.